US firm TPG buys 50% of Russia's SIA for $800M

13 April 2008

In what is believed to be the largest private equity investment in Russia, the Texas, USA-based firm TPG Capital has made a bid to acquire 50% of Moscow-headquartered drug wholesaler SIA International for about $800.0 million in cash.

The majority owner of the wholesaler is Igor Rudinsky, who will retain the post of chief executive and will join the firm's board as chairman, as well as keeping part of the company in his hands. There will be a total of eight board members, four from each partner.

With the Russian pharmaceutical market valued at about $12.4 billion in 2007, up 16% on the previous year, SIA generates around 90% of its $2.7 billion annual revenues from supplying the country's more than 30,000 pharmacists through a network of 41 regional subsidiaries and has an overall 25% market share. It also supplies hospitals and has its own drug manufacturing facilities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight